The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.

Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.

Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.

Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.